

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

# <sup>25</sup> **Abstract**

26

27 High blood level of low-density lipoprotein cholesterol (LDL-C) is a major risk factor for 28 cardiovascular disease. Although genetic variants linked to high LDL-C have been studied in other 29 populations, there have been no previous studies among Filipinos. This study aims to determine 30 the association of candidate genetic variants to high LDL-C. We performed an age- and sex-31 matched case-control study that compared Filipino participants with high LDL-C levels (n=60) 32 with controls (n=60). DNA was extracted from blood samples and genotyped for candidate SNPs 33 using a customized microarray chip. Logistic regression analyses were used to determine the 34 composite association of genetic and clinical variables to the condition. Of the initial eleven SNPs 35 associated with high LDL-C in univariate analyses, only the variant rs9644568 in the intergenic 36 region downstream of the *LPL* gene remained significantly associated with high LDL-C levels 37 on multiple regression analysis and variable selection after adjustment for hypertension. The G 38 allele was observed as the risk allele in a recessive model. The variant rs9644568-G in the *LPL*  39 gene was associated with high blood LDL-C levels among Filipinos. In combination with 40 hypertension, this genetic profile may identify individuals who are susceptible to develop high 41 LDL-C in this population.

42

43 \* Corresponding author

44 E-mail: eccutiongcodelapaz@up.edu.ph

# **Introduction**

 Low-density lipoprotein cholesterol (LDL-C) level is a risk factor and a traditional target for preventive cardiovascular disease (CVD) interventions. This association is enhanced in the presence 49 of atherosclerosis [1], and the common view is that it is an active component of atherogenesis [2]. 50 Several studies have since reported reduced adverse cardiovascular events after treatment with LDL-51 C-lowering drugs [2-4].

 LDL-C levels may be affected by several factors, including genetics. A common familial form of LDL-C elevation, familial hypercholesterolemia (FH), has been well studied and three causative genes have already been identified, namely *low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9)*. In addition, several studies on hereditary dyslipidemias have shown a variety of genes involved, such *as low density lipoprotein receptor adaptor protein 1 (LDLRAP1), ATP binding cassette subfamily G members 5 and 8* 

*(ABCG5, ABCG8), angiopoietin like 3 (ANGPTL3), microsomal triglyceride transfer protein* 

*(MTTP), myosin regulatory light chain interacting protein (MYLIP), apolipoproteins A5, B, C2 and* 

*E (APOA5, APOB, APOC2, APOE), and lipoprotein lipase (LPL)*, which as expected, are involved in

lipid metabolism, transport and processing [5,6].

 Genotyping efforts in recent years attempted to find possible genetic susceptibility loci. For instance, genome-wide association studies (GWAS) have implicated *LDLR*, *APOE*, and *3-hydroxy-3- methylglutaryl-coenzyme A reductase* (*HMGCR*) as possible key regulators of lipid metabolism to high LDL-C [7-9]. Other genes that were considered include *fatty acid desaturase 1* (*FADS1*), *polypeptide N- acetylgalactosaminyltransferase 2* (*GALNT2*), and a*cetyl-coenzyme A carboxylase beta* (*ACACB*) [10-12].

 However, findings from studies of genetic polymorphisms cannot be generalized across populations due to inherent inter-ethnic differences in genetic profiles. To illustrate, among the Taiwanese population, a *PCSK9* variant has been determined to have a causally significant association with high LDL-C levels; however, this association is not found among the Italian population [13,14]. In another study, a novel polymorphism of the *ICAM1* was reported to be

 associated with LDL-C in African Americans at conventional genome-wide significance, but not among Hispanics and East Asians [15]. Such discrepancies warrant verifying associations between genotypes and LDL-C levels in newly investigated populations. This could be due to independently evolved genetic differences with similar phenotypes due to metabolic proximity. Data from different ethnic populations will be able to contribute to a better understanding of diseases and can enhance customized clinical applications for individual populations.

 Due to scarce data on genetic associations with LDL-C among Filipinos, this study aimed to identify candidate genetic markers associated with high LDL-C levels in this population. In addition to direct association, the variants were interpreted in the context of traditional risk factors to account for their significant, but potentially interdependent influences.

- **Methodology**
- 
- 

### **Study design and ethics clearance**

 This is an age- and sex-matched case-control study performed from July 9, 2013 to March 31, 2017. This study complied to the Principles of the Declaration of Helsinki (2013) and all experimental protocols in this study were approved by the University of the Philippines Manila- Research Ethics Board (Study protocol code UPMREB- 2012-0186-NIH). The investigators confirm that the methods complied with the relevant guidelines and regulations of UPMREB.

### **Enrollment of participants and clinical data collection**

94 Participants were enrolled from the Philippine General Hospital, different local communities, 95 and clinics in Metro Manila. They were unrelated, aged 18 years old and above, of Filipino descent 96 up to the 3rd degree of consanguinity, and could provide independent consent. Cases were defined as 97 (a) having at least one reading of serum LDL-C  $\geq$ 160 mg/dl as defined by the NCEP ATP III 98 guidelines; and (b) had not ever been on antilipidemics. Controls were participants with (a) at least 99 one reading of serum LDL-C <160 mg/dl; and (b) without a previous diagnosis of dyslipidemia. 100 Participants were excluded if they had end-stage renal disease, decompensated chronic liver disease, 101 active malignancy, chronic lung disease, secondary hypertension, secondary dyslipidemia, or if 102 pregnant. The demographic data and clinical characteristics were obtained from patient records and

5

103 verbal interviews. Clinical data, including lipid profile and serum creatinine, were also recorded. 104 Written informed consent forms duly approved by the UPMREB was obtained from potential 105 participants prior to recruitment to the study.

107

### <sup>106</sup> **DNA extraction and quantification**

108 DNA was extracted using the QiaAmp DNA Mini Kit following the spin protocol for blood 109 buffy coat as specified in the manufacturer's instruction manual. DNA was quantified using a 110 spectrometer at 260nm and stored at -20°C until use. All DNA samples had A-260nm/A-280nm values 111 above 1.80.

113

# <sup>112</sup> **Customized genotyping**

114 A customized GoldenGate Genotyping (GGGT) beadchip (Illumina, Inc., San Diego, CA, 115 USA) was designed in 2012 using candidate SNPs from both coding and noncoding regions, 116 including intergenic and intronic SNPs, which have shown evidence of association with high LDL-117 C levels and lipid metabolism. These were selected after an extensive search in the following databases: 118 Pharmacogenomics Knowledgebase database (PharmGKB), National Human Genome Research 119 Institute Genome-Wide Association Study Catalog (NHGRI GWAS Catalog), PubMed, and selected 120 international patent databases (e.g., Patentscope and Espacenet). The selected SNPs were submitted 121 to Illumina, Inc. for scoring to determine the suitability of the SNPs to discriminate for microarray 122 assay and to estimate their specificity.

123 Customized genotyping of candidate SNPs was performed using DNA microarray 124 technology following the GoldenGate Genotyping (GGGT) protocol specified in the manufacturer's 125 manual. While the microarray platform is optimally designed to detect bi-allelic SNPs, the study 126 included tri- or quad-allelic SNPs using the reference allele and the most common alternative in cases 127 where the variants correlate with significant clinical outcomes. After microarray processing, the 128 beadchip was imaged on the HiScan System, and data from these images were analyzed using 129 GenomeStudio software.

130

#### 6

#### <sup>132</sup> **Data analysis**

133

135

141

143

#### 134 **Quality control**

136 GenomeStudio 2.0 and PLINK version 2.05.10 were used for data cleanup using the 137 following criteria: call rates  $\geq$  95%, minor allele frequency (MAF) of  $\geq$  0.01, genotype missingness of  $\leq 0.05$ , individual missingness  $\leq 0.05$ , and not having a Hardy-Weinberg  $\frac{138}{139}$ 140 equilibrium (HWE) of  $p \le 0.001$  in the control group.

#### 142 **Statistical analysis**

144 Chi-squared test and Fisher exact test, as applicable, were used for categorical data, and the 145 student *t-test* was used for quantitative data were performed to assess for significant differences 146 between alleles and genotypes (i.e., allelic and genotypic association tests, which include additive, 147 dominant and recessive models). These models were identified based on the distribution of the case 148 and control genotypes. Tests for allelic and genotypic associations were done by setting the cut-off 149 at Bonferroni-corrected p < 0.05.

150 Upon determination of genotypic effects, the genotypes were recorded according to the most 151 significant model, with imputations made for missing data. Univariate analysis was done to determine 152 the association of SNPs with high LDL-C phenotype. A multiple logistic regression using stepwise 153 backward elimination was performed with nominal p < 0.05 and clinical variable with p < 0.20.

### <sup>154</sup> **Results**

155

156 After data quality control, the final set of samples for analysis included 120 participants 157 consisting of 60 cases and 60 controls (Fig 1A). Using age- and sex-matched case-control design, 158 the 120 participants were genotyped using 132 genomic variants.

159 Of the 132 variants selected for the study, 50 variants were removed after quality control 160 with PLINK: 33 SNPs failed the Hardy-Weinberg test (*p* > 0.001) among controls, ten SNPs had 161 missing genotype data for more than 5% of the individuals, and one SNP was removed because the 162 minor allele frequency was lower than 1% (Fig 1B). Eleven variants were significantly associated 163 with high LDL-C after adjusting for multiple testing (i.e., Bonferroni-adjusted  $\alpha = 0.05$ ).

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.12.24307253;](https://doi.org/10.1101/2024.05.12.24307253) this version posted May 13, 2024. The copyright holder for this preprint





167 **FIG 1. Schematic diagram of data processing and analysis for the high LDL-C group.** A total  $\overline{B}$ 168 of 183 participants (A) and 132 SNPs (B) were analyzed to determine the association of genetic 169 variants with high LDL-C and lipid metabolism. Abbreviations: MIND – individual missingness; 170 SNP – single nucleotide polymorphism; HWE – Hardy-Weinberg equilibrium; GENO – genotypic 171 missingness 172

173 Table 1 summarizes the clinical characteristics of the included participants. Their crude 174 odds ratios are in Table S1. Participants in the high LDL-C group tend to have more comorbidities 175 that showed significance such as hypertension ( $p < 0.0001$ ), BMI  $\geq 25$  kg/m<sup>2</sup> ( $p = 0.056$ ), and 176 ischemic heart disease (*p* = 0.002). The cases also seemed to have slightly elevated creatinine levels.

177





It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.12.24307253;](https://doi.org/10.1101/2024.05.12.24307253) this version posted May 13, 2024. The copyright holder for this preprint

8

Abbreviations: SD – standard deviation; BMI – body mass index; eGFR – estimated glomerular filtration rate; HDL – high-density lipoprotein; LDL – low-density lipoprotein \*Significance set at *p* < 0.05 using Chi-squared test for age and sex, conditional logistic regression for comorbidities and lifestyle factors, and Student's *t* test for continuous variables 179 There were 11 variants found to have a statistically significant association with LDL-C 180 levels on the genotypic association test after adjusting for multiple testing (Bonferroni-adjusted *α*  $181 = 0.00061$  (Table S2). These variants underwent logistic regression analysis for the computation 182 of their OR and to determine which will retain significance upon adjusting for other variables (Table 183 2). One SNP had clinically significant odds ratios (OR ≥ 2.5) and was statistically significant (*p*  184  $\leq$  001) on simple logistic regression analysis: rs12279250 in NELL1. This SNP seemed to display 185 a dominant genotypic effect. Clinical variables with a significant difference between the two groups,  $p \le 0.20$ : 189 hypertension, BMI  $\geq$  25 kg/m<sup>2</sup>, and ischemic heart disease were included together with the 11 191 variants with nominal *p <* 0.05 in the full model for the multiple regression analysis (Table 3). On 192 variable selection using the stepwise algorithm (*p <* 0.05), only the presence of hypertension and

178

186

187<br>188

190

193 rs9644568 retained their significant association with high LDL-C levels under an additive model 194 with allele G as the risk allele (AG vs. GG: adjusted OR = 2.44, 95% CI = 0.41-20.60; *p* = 0.355; **TABLE 2. Univariate logistic regression analysis of the significant variants**



195 GG vs AA: adjusted OR = 10.66, 95% CI = 2.15-81.05; *p* = 0.008) (Table 4).



9



*ABCB1* = ATP binding cassette subfamily B member 1; *ABCA1* = ATP binding cassette subfamily A member 1; *ABCG8* = ATP binding cassette subfamily G member 8; *APOB* = apolipoprotein B; *CELSR2* = cadherin EGF LAG seven-pass G-type receptor 2; CI = confidence interval; *CYP3A5* = cytochrome P450 family 3 subfamily A member 5; *GOLIM4* = golgi integral membrane protein 4; *INTS10* = integrator complex subunit 10; *LIPC* = lipase C; *LPL* = lipoprotein lipase; *NELL1* = neural EGFL like 1; *SLC18A1* = solute carrier family 18 member A1; SNP = single nucleotide polymorphism; *ZPR1* = zinc finger protein ZPR1;

\*Significance set at p < 0.05 on conditional logistic regression analysis

#### 196

#### **TABLE 3. Genetic variants and clinical factors in the multiple regression full model.**







BMI = body mass index; CI = confidence interval; OR = odds ratio

197 198

#### **TABLE 4. Genetic variants and clinical factors remaining after variable selection.**



199 ∗Significance set at p< 0.05; Abbr: CI = confidence interval; OR = odds ratio

200

202

# <sup>201</sup> **Discussion**

203 Genetic determinants of high LDL-C may be helpful in the understanding and optimum 204 management of cardiovascular risk. As associated variations often differ across populations, 205 especially for complex conditions, studies on Filipinos must be undertaken considering that 206 cardiovascular disease remains as the top cause of mortality in the country. This study analyzes 207 candidate genetic variants of high LDL-C among Filipino patients. In addition, a regression model of 208 candidate genetic variants incorporating traditional clinical risk factors was generated to assess their 209 relative effects on LDL-C profiles.

 Univariate analyses found 11 variants associated with LDL-C levels. The reported genes include *lipoprotein lipase* (*LPL*), *ATP binding cassette subfamily B member* (*ABCB1*), *lipase C*  (*LIPC*), *ATP binding cassette subfamily A member* (*ABCA1*), *ATP binding cassette subfamily G member 8* (*ABCG8*), *apolipoprotein B* (*APOB*), and *cadherin EGF LAG seven-pass G-type receptor 2* (*CELSR2*). Expectedly, these are known genes whose roles in LDL-C metabolism are well established — from lipid transport, cellular metabolism and homeostasis, cellular translocation, and storage [16-21].

11

217 A major finding in this study is the variant rs9644568 near the *LPL* gene. Logistic 218 regression with adjustment for hypertension shows a significant association of rs9644568 to high 219 LDL-C levels after adjusting for hypertension among Filipinos. The G allele of rs9644568 confers 220 a 2.44-fold increased risk for high LDL-C in heterozygous individuals and a 10.66-fold increased 221 risk in homozygous individuals. This suggests a possible additive or a multiplicative model of 222 transmission. This is similar to the findings of a genome-wide association study among Europeans, 223 which consistently demonstrated the significant association of G allele of rs4977574 with high LDL-224 C levels and an increased risk of myocardial infarction (MI) [22]. In contrast, the minor G allele 225 protects LDL-C in another study that included Hispanics, East Asians and also Europeans [23]. A 226 similar study found the minor G allele to be associated with decreased risk for coronary artery 227 disease and peripheral artery disease in a Chinese population with diabetes [24].

228 The SNP rs9644568 is located on chromosome 8p21.3 in an intergenic region downstream 229 of the gene *LPL* (UCSC Genome Browser, [http://genome.ucsc.edu.](http://genome.ucsc.edu/) Accessed October 10, 230 2023). Although the variant is >100 kb far from the gene LPL, expression from several tissues 231 suggests that it regulates the gene (GTEx Portal. [https://gtexportal.org.](https://gtexportal.org/) Accessed October 10, 2023). 232 This gene is predominantly expressed in the heart, skeletal muscles, and adipose tissues<sup>25</sup>. *LPL* 233 encodes a rate-limiting enzyme called lipoprotein lipase, which plays an important role in lipid 234 metabolism, as well as in lipid intake and clearance. Lipoprotein lipase aids in the breakdown of 235 the circulating triglyceride-rich lipoproteins in the bloodstream and the uptake of free fatty acids 236 into peripheral organs for energy storage and consumption [26-30]. Alterations in LPL activity 237 could result in dyslipidemia, characterized by increased plasma LDL-C, TG, and reduced plasma 238 HDL-C levels [31]. This association of the variant is interesting, as prior data, to our knowledge, do 239 not indicate rs9644568 as a risk marker for high LDL levels or as having the highest odds ratio in 240 any non-Filipino population. This can imply that the variant is a unique risk marker for Filipinos, 241 independent of other components of metabolic syndrome, i.e., hypertension and diabetes mellitus.

242 To support the significance of *LPL* as a candidate locus, the study also indicated that another 243 downstream *LPL* variant*,* rs7016880, was associated with LDL-C. Interestingly, rs7016880 shares

12

244 many characteristics with rs9644568 – being located as a downstream non-coding regulator, 245 having a possible multiplicative model, with a high odds ratio. This may provide greater confidence 246 for the veracity of the findings in this study.

247 As for the other variants, the adjustments due to hypertension and the rs9644568 seem to 248 mask their statistical significance. This has several implications. First, rs9644568 is rarely reported 249 as a marker for LDL-C in the literature, but the statistical significance of rs9644568 stood out 250 prominently in the current study, thus implying that the SNP is unique among the Filipino 251 population. Second, hypertension might have masked the statistical significance of some of the 252 candidate genes in the metabolic syndrome context. This is unsurprising as some variants have been 253 previously associated with high blood pressure. To illustrate, *ABCBI* was reported to be associated 254 with hypertension through dietary salt transport and retention [32]. In a study among Han Chinese, 255 variants of *ABCA1*, rs2472510 and rs2515614, were associated with hypertension, with decreased 256 expression of *ABCA1* linked with hypertension risk [33]. On the other hand, meta-analysis of 2799 257 cases and 6794 controls showed an association of *CYP3A5* rs776746 with hypertension [34]. A later 258 study on a small sample of Han Chinese also reported a significant association of *CYP3A5* rs776746 259 with the elevated risk of hypertension [35].

 Several variants are mostly known genes whose roles in LDL-C metabolism are well established [16-21]. The G allele of rs1532085 in *LIPC* with a protective effect for LDL-C levels in Chinese populations [36], is similar to the findings in this study. In a large GWAS study involving >100,000 Caucasians, rs4299376 in *ABCG8* was found to be one of the strongly associated genes with LDL-C [38]. The variant rs676210 in *APOB* has been identified as a susceptibility locus for very low-density lipoprotein levels in the Women's Genome Health Study (WGHS) involving 17,296 women of European ancestry [38]. This association was further reported in the Chinese Yugur population<sup>39</sup>. A GWAS study of 11,685 showed a significant association of *CELSR2* rs660240 to LDL-C levels where the G allele is associated with risk and this was confirmed in a meta-analysis of Below et al. (2016) [40,41].

270 However, some genes can be considered as attractive at best at this point. One intriguing

 finding is the direct association of ABCB1 with LDL-C. There is scarce data on this association, as most studies focused on its association with response to statins [42,43]. The variant ABCB1 rs1045642 is by itself associated with statin response [44]. The variant rs12279250 in NELL1, a growth factor of still uncertain significance, has been associated with increased triglyceride levels [45,46], which may lead to a subsequent increase in LDL-C levels. Despite the study identifying rs4149268 in ABCA1 as associated with LDL-C, most studies reported an association with HDL- C levels instead of LDL-C [47]. This may need to be verified, but it is noteworthy to investigate if such an association remains among Filipinos. As for rs776746 in CYP3A5, there is little study on the direct association with LDL-C levels. This could be due to the assumption that cytochrome P proteins are mainly associated with drugs. In fact, most studies focused on response to cholesterol- lowering drugs [48,49]. As the present study focused on participants without drug intake, a possible role for CYP3A5 on LDL-C level could be plausible. Similarly, there is minimal information on rs2686586. Even its association with the gene GOLIM4 is questionable, as no evidence of regulation nor proximity (>50kb) is noted in the literature. Nonetheless, the fact that it is significantly associated with LDL- C needs to be verified.

 In this study, clinical variables that show a significant association with high LDL-C 287 phenotype are hypertension, BMI  $> 25 \text{ kg/m2}$ , and ischemic heart disease (IHD). Several studies consistently show strong correlations between these comorbidities and LDL-C levels. The link between LDL-C and hypertension was elucidated by the group of Laaksonen et al. (2008). They reported that elevated serum levels of LDL-C increase the risk of hypertension in Finnish men, which explained the strong association of dyslipidemia with incident hypertension[50]. Meanwhile, a previous study performed in the US population suggested a linear association of LDL-C concentrations and BMI [51]. The association between high LDL-C levels and high IHD risk is further substantiated by the study of Breuer (2005), focusing on improving cardiovascular disease outcomes by lowering LDL-C levels[52]. Moreover, dyslipidemia and hypertension are known as major risk factors for cardiovascular diseases; with these two comorbidities reported to be frequently diagnosed in patients with ischemic heart disease [53].



304<br>305 Genetic determinants largely influence the development of high LDL-C levels. This study found an association of variant rs9644568 in the intergenic region downstream of the *LPL* gene, with high LDL-C levels among Filipinos. Adding a genetic component may improve screening and 308 assessment of patients at risk for developing high LDL-C levels.

# <sup>309</sup> **References**

- 310 311 [1] Mortensen MB, Dzaye, O., Bøtker, H.E., et al. Low-Density Lipoprotein Cholesterol Is 312 Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients 313 With Evidence of Coronary Atherosclerosis: The Western Denmark Heart Registry.
- 314 Circulation. 2023; 147(14): 1053-1063.
- 315 [2] Stanciulescu LA, Scafa-Udriste A & Dorobantu M. Exploring the Association between Low-
- 316 Density Lipoprotein Subfractions and Major Adverse Cardiovascular Outcomes-A 317 Comprehensive Review. Int J Mol Sci. 2023; 24(7): 6669.
- 318 [3] Abdullah SM, Defina LF, Leonard D, et al. Long-Term association of low-density lipoprotein
- 319 cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic
- 320 cardiovascular disease: results from the Cooper Center Longitudinal Study. Circulation. 2018; 321 138(21): 2315-25.
- 322 [4] Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate 323 coronary heart disease risk. Journal of the American College of Nutrition. 2008; 27: 1–5.
- 324 [5] Brown EE, Sturm AC, Cuchel M, et al. Genetic testing in dyslipidemia: A scientific statement 325 from the National Lipid Association. J Clin Lipidol. 2020; 14(4): 398-413.
- 326 [6] García-Giustiniani D, Stein R. Genetics of Dyslipidemia. Arq Bras Cardiol. 2016; 106(5): 434- 327 438.
- 328 [7] Lipkin SM, Chao EC, Moreno V, et al. Genetic variation in 3-hydroxy-3methylglutaryl CoA 329 reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev 330 Res (Phila). 2010; 3(5): 597-603.
- 331 [8] Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid levels and coronary heart 332 disease risk in 16 European population cohorts. Nat Genet. 2009; 41(1): 47-55.
- 333 [9] Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridket PM 334 Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004; 291(23): 335 2821-27.
- 336 [10] Ruaño G, Thompson PD, Kane, J.P., et al. Physiogenomic analysis of statin-treated

- 337 patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein 338 cholesterol? Pharmacog. 2010; 11(7): 959-7.
- 339 [11] Waterworth DM, Ricketts SL, Song K, et al. Genetic variants influencing circulating lipid 340 levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol. 2010; 30(11), 341 2264-76.
- 342 [12] Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid 343 concentrations and risk of coronary artery disease. Nat Genet. 2008; 40(2): 161-9.
- 344 [13] Hsu LA, Teng MS, Wu S, et al. Common and Rare PCSK9 Variants Associated with Low-
- 345 Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian 346 Randomization Study. International Journal of Molecular Sciences. 2022; 23(18): 10418.
- 347 [14] Guella I, Asselta R, Ardissino D, et al. Effects of PCSK9 genetic variants on plasma LDL 348 cholesterol levels and risk of premature myocardial infarction in the Italian population. J. 349 Lipid Res. 2010; 51: 342–3349.
- 350 [15] Elbers CC, Guo Y, Tragante V, et al. Gene-Centric Meta-Analysis of Lipid Traits in 351 African, East Asian and Hispanic Populations. PLoS ONE. 2012; 7(12): e50198.
- 352 [16] Wu J, Wang X, Chen H, et al. Type 2 Diabetes Risk and Lipid Metabolism Related to the 353 Pleiotropic Effects of an ABCB1 Variant: A Chinese Family-Based Cohort Study. 354 Metabolites. 2022; 12: 875.
- 355 [17] Dijk W, Di Filippo M, Kooijman S, et al. Identification of a Gain-of-Function LIPC Variant 356 as a Novel Cause of Familial Combined Hypocholesterolemia. Circulation. 2022; 146(10): 357 724-739.
- 358 [18] Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ, et al. The Role of the ATP-359 Binding Cassette A1 (ABCA1) in Human Disease. Int J Mol Sci. 2021; 22(4): 1593.
- 360 [19] Benn M, Nordestgaard BG, Jensen JS, et al. Polymorphism in APOB Associated with 361 Increased Low-Density Lipoprotein Levels in Both Genders in the General Population. The 362 Journal of Clinical Endocrinology & Metabolism. 2005; 90(10): 5797–5803.
- 363 [20] Tada H, Okada H, Nomura A, et al. Beneficial effect of ezetimibe-atorvastatin combination
- 364 therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis. 2020;





425 impact on efficacy and safety. Per Med. 2023; 20(1): 65-86.

- 426 [44] Sun L, Wolska A, Amar M, et al. Approach to the Patient With a Suboptimal Statin 427 Response: Causes and Algorithm for Clinical Management. J Clin Endocrinol Metab. 2023; 428 108(9): 2424-2434.
- 429 [45] Cheng X, Shi J, Jia Z, et al. NELL-1 in Genome-Wide Association Studies across Human 430 Diseases. Am J Pathol. 2022; 192(3): 395-405.
- 431 [46] Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, et al. Genome-wide association 432 analyses suggest NELL1 influences adverse metabolic response to HCTZ in African 433 Americans. Pharmacogenomics J. 2014; 14(1): 35-40.
- 434 [47] Paththinige CS, Sirisena ND, Dissanayake V. Genetic determinants of inherited 435 susceptibility to hypercholesterolemia - a comprehensive literature review. Lipids Health Dis. 436 2017; 16(1): 103.
- 437 [48] Jiang XY, Zhang Q, Chen P, et al. CYP7A1 polymorphism influences the LDL cholesterol-438 lowering response to atorvastatin. J Clin Pharm Ther. 2012; 37(6): 719-23.
- 439 [49] Lim MYC, Tee JR, Yau WP, et al. A meta-analysis of the pooled impact of CYP7A1 single 440 nucleotide polymorphisms on serum lipid responses to statins. Front Genet. 2023; 14: 441 1199549.
- 442 [50] Laaksonen DE, Niskanen L, Nyyssönen K, et al. Dyslipidaemia as a predictor of 443 hypertension in middle-aged men. Eur Heart J. 2008; 29(20): 2561-8.
- 444 [51] McLaughlin T, Allison G, Abbasi F, et al. Prevalence of insulin resistance and associated 445 cardiovascular disease risk factors among normal weight, overweight, and obese individuals. 446 Metabolism. 2004; 53(4): 495-9.
- 447 [52] Breuer HW. Low Density Lipoprotein Cholesterol and Coronary Heart Disease Lower is 448 Better. European Cardiology. 2005; 1(1): 1-6.
- 449 [53] Singh BM, Mehta JL. Interactions Between the Renin-Angiotensin System and 450 Dyslipidemia: Relevance in the Therapy of Hypertension and Coronary Heart Disease. Arch 451 Intern Med. 2003; 163(11): 1296–1304.
- 452
- 453

<sup>454</sup> **Acknowledgements** 455

456 The authors would like to express their sincere gratitude to the administrative staff and 457 researchers of the Microarray Laboratory of the Institute of Human Genetics, National Institutes 458 of Health-University of the Philippines Manila, the Philippine Genome Center, and the clinical 459 fellows of the Department of Medicine for actively being involved in the project. We are 460 extending our gratitude to our sponsor, the Philippine Council for Health Research and 461 Development of the Department of Science and Technology (PCHRD-DOST)

<sup>462</sup> **Author Contributions**

463 **EMCutiongco-De La Paz**, conceptualized the study and designed the methodology, acquired 464 funding and led the project administration and supervision, conducted the research and 465 investigation process, performed the data curation and analysis, interpreted the data, wrote the 466 original draft, reviewed and edited the manuscript for intellectual content; **JBNevado** 467 conceptualized the study and designed the methodology, acquired funding and led the project 468 administration and supervision, conducted the research and investigation process, performed the 469 data curation and analysis, interpreted the data, wrote the original draft, reviewed and edited the 470 manuscript for intellectual content; **LEGSantos**, conceptualized the study and designed the 471 methodology, conducted the research and investigation process, interpreted the data; 472 **AYCLAman**, acquired funding and led the project administration and supervision, conducted the 473 research and investigation process, performed the data curation and analysis, interpreted the data, 474 wrote the original draft; **JDAMagno**, conceptualized the study and designed the methodology, 475 conducted the research and investigation process, interpreted the data; **PMMReganit,** 476 conceptualized the study and designed the methodology, conducted the research and investigation 477 process, interpreted the data; **RHPTiongco**, conceptualized the study and designed the 478 methodology, conducted the research and investigation process, interpreted the data; **DIDOna**, 479 conceptualized the study and designed the methodology, conducted the research and investigation 480 process, interpreted the data; **FERPunzalan**, conceptualized the study and designed the 481 methodology, conducted the research and investigation process, interpreted the data; **EJBLlanes**,

482 conceptualized the study and designed the methodology, conducted the research and investigation 483 process, interpreted the data; **JAMAherrera**, conducted the research and investigation process, 484 interpreted the data; **CMOFernandez**, performed the data curation and analysis, interpreted the 485 data, reviewed and edited the manuscript for intellectual content; **LLAbrahan**, conducted the 486 research and investigation process, interpreted the data; **CFAgustin**, conducted the research and 487 investigation process, interpreted the data; **AJPBejarin**, conducted the research and investigation 488 process, performed the data curation and analysis, interpreted the data, wrote the original draft; 489 **RGSy**, conceptualized the study and designed the methodology, acquired funding and led the 490 project administration and supervision, conducted the research and investigation process, 491 interpreted the data, reviewed and edited the manuscript for intellectual content

# <sup>492</sup> **Data Availability Statement**

- 493 The datasets used and/or analyzed during the current study are available from the corresponding
- 494 author on reasonable request.

# <sup>495</sup> **Competing Interests**

496 The authors declare no competing interests.

# <sup>497</sup> **Funding Source**

- 499 The present study was sponsored by a grant-in-aid from the PCHRD-DOST
- 500